9,789 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Bought by Shilanski & Associates Inc.

Shilanski & Associates Inc. bought a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 9,789 shares of the company’s stock, valued at approximately $216,000.

Other large investors have also made changes to their positions in the company. Stifel Financial Corp increased its holdings in Teva Pharmaceutical Industries by 54.0% during the third quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock valued at $1,196,000 after buying an additional 23,283 shares during the last quarter. Thrivent Financial for Lutherans grew its position in shares of Teva Pharmaceutical Industries by 21.8% during the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock valued at $4,046,000 after acquiring an additional 40,218 shares during the period. Sio Capital Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth $24,314,000. CWA Asset Management Group LLC bought a new position in Teva Pharmaceutical Industries in the 4th quarter worth $3,340,000. Finally, Two Sigma Advisers LP lifted its position in Teva Pharmaceutical Industries by 15.3% during the third quarter. Two Sigma Advisers LP now owns 1,034,500 shares of the company’s stock valued at $18,642,000 after purchasing an additional 137,000 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the sale, the executive vice president now directly owns 44,104 shares in the company, valued at $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at $15,296,950. This trade represents a 29.15 % decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Stock Down 1.2 %

Shares of NYSE TEVA opened at $21.75 on Friday. The firm’s fifty day moving average is $19.53 and its two-hundred day moving average is $18.32. Teva Pharmaceutical Industries Limited has a 52-week low of $11.48 and a 52-week high of $22.80. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57.

Analysts Set New Price Targets

Several research analysts have recently commented on TEVA shares. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 18th. JPMorgan Chase & Co. raised their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Piper Sandler upped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. UBS Group raised their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Barclays upped their target price on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and an average target price of $22.63.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.